Element Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Element Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-27,400	Closed	-$115K	–	1051
2018 Q3	$115K	Sell	27,400 -35,178	-56%	-$148K	﹤0.01%	837
2018 Q2	$242K	Buy	+62,578	New	+$416K	0.01%	644

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Element Capital Management's MACK Position: Q4 2018 in Review

Element Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 27,400 shares — an estimated $115K sold.

Element Capital Management first reported a position in MACK in Q2 2018 and held it in 2 quarters. The position peaked at $242K in Q2 2018. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Element Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Element Capital Management sold 27,400 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $115K.
Element Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
Element Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $242K in Q2 2018.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.